Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists

• Authors: Mohammad E Mohammad, Kasr Al-Aini Hospital; Joaquin A Vizcarra, Emory University; Xiomara Garcia, Cleveland Clinic Foundation; Shnehal Patel, OhioHealth; Adam Margolius, Cleveland Clinic Foundation; Xin Xin Yu, Cleveland Clinic Foundation; Hubert H Fernandez, Cleveland Clinic Foundation
• Journal Title: Clinical Parkinsonism and Related Disorders
• Volume: Volume 4
• Publisher: Elsevier | 2021-01-01, Pages 100091-100091
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.prdoa.2021.100091
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Dopamine agonist; Dopamine agonist withdrawal syndrome; Impulse control behavior disorder; Parkinson disease

Abstract

Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral. Behavioral side effects include: impulse control behavior disorder (ICD), psychosis and cognitive impairment. Non-behavioral side effects include: nausea/vomiting, “sleep attacks”, leg swelling, weight gain and orthostasis. The aim of this study is to evaluate the clinicians’ response to PD patients who developed behavioral side effects from dopamine agonists, in comparison to those patients who developed only non-behavioral side effects. We performed a retrospective chart review of all patients diagnosed with PD over a two year period. Among 313 patients who were on a dopamine agonist, 156 reported side effects. Sixty-five patients reported behavioral (with or without non-behavioral) side effects, while 91 experienced only non-behavioral side effects. Forty-nine out of the 65 patients (75.3%) who experienced behavioral side effects had their dopamine agonist dose decreased compared to 53 out of 91patients (58.2%) who experienced only non-behavioral side effects (Chi square = 4.92, p < 0.05). Patients with behavioral side effects were 3 times more likely have their dose decreased (OR = 3.3; 95%CI = 1.442–7.551; P = 0.005). However, neither taper speed nor the occurrence of dopamine agonist withdrawal syndrome (DAWS) differed between the two groups. Amongst PD patients treated with dopamine agonists, the presence of behavioral side effects independently increased the chance of dopamine agonist dose reduction. Prospective studies are needed to confirm these findings.